Disc Medicine (IRON) Stock Forecast, Price Target & Predictions

IRON Stock Forecast

Disc Medicine stock forecast is as follows: an average price target of $72.50 (represents a 15.72% upside from IRON’s last price of $62.65) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

IRON Price Target

The average price target for Disc Medicine (IRON) is $72.50 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $112.00 to $43.00. This represents a potential 15.72% upside from IRON's last price of $62.65.

IRON Analyst Ratings

Buy

According to 12 Wall Street analysts, Disc Medicine's rating consensus is 'Buy'. The analyst rating breakdown for IRON stock is 0 'Strong Buy' (0.00%), 11 'Buy' (91.67%), 0 'Hold' (0.00%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

Disc Medicine Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Greg Harrison	Scotiabank	$70.00	$64.78	8.06%	11.73%
Nov 05, 2024	Evan David Seigerman	BMO Capital	$112.00	$63.24	77.10%	78.77%
Oct 23, 2024	Roger Song	Jefferies	$89.00	$50.92	74.78%	42.06%
Sep 16, 2024	Douglas Tsao	H.C. Wainwright	$70.00	$47.79	46.47%	11.73%
Aug 22, 2024	Tiago Fauth	Wells Fargo	$75.00	$49.31	52.10%	19.71%
Aug 08, 2024	Danielle Brill	Raymond James	$50.00	$42.85	16.69%	-20.19%
Jun 17, 2024	Evan David Seigerman	BMO Capital	$70.00	$45.80	52.84%	11.73%
May 10, 2024	Danielle Brill	Raymond James	$43.00	$29.95	43.57%	-31.36%
Apr 02, 2024	Evan David Seigerman	BMO Capital	$50.00	$34.21	46.16%	-20.19%
Apr 01, 2024	Ben Burnett	Stifel Nicolaus	$71.00	$34.21	107.54%	13.33%

Row per page

Go to

The latest Disc Medicine stock forecast, released on Nov 05, 2024 by Greg Harrison from Scotiabank, set a price target of $70.00, which represents a 8.06% increase from the stock price at the time of the forecast ($64.78), and a 11.73% increase from IRON last price ($62.65).

Disc Medicine Price Target by Period

	1M	3M	12M
# Anlaysts	3	5	12
Avg Price Target	$90.33	$83.20	$65.25
Last Closing Price	$62.65	$62.65	$62.65
Upside/Downside	44.18%	32.80%	4.15%

In the current month, the average price target of Disc Medicine stock is $90.33, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 44.18% increase as opposed to Disc Medicine's last price of $62.65. This month's average price target is up 8.57% compared to last quarter, and up 38.44% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 05, 2024	Scotiabank	Sector Outperform	Sector Outperform	Hold
Oct 23, 2024	Jefferies	-	Buy	Initialise
Oct 16, 2024	Scotiabank	-	Outperform	Initialise
Sep 16, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 22, 2024	Wells Fargo	-	Overweight	Initialise
Aug 08, 2024	Raymond James	Outperform	Outperform	Hold
Jun 14, 2024	Wedbush	Outperform	Outperform	Hold
Jun 13, 2024	BMO Capital	Outperform	Outperform	Hold
May 10, 2024	Raymond James	Outperform	Outperform	Hold
Apr 02, 2024	BMO Capital	Outperform	Outperform	Hold

Row per page

Go to

Disc Medicine's last stock rating was published by Scotiabank on Nov 05, 2024. The company gave IRON a "Sector Outperform" rating, the same as its previous rate.

Disc Medicine Financial Forecast

Disc Medicine Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Disc Medicine's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IRON's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Disc Medicine EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

undefined analysts predict IRON's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Disc Medicine's previous annual EBITDA (undefined) of $NaN.

Disc Medicine Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-
Avg Forecast	$-38.02M	$-40.56M	$-37.98M	$-34.13M	$-36.16M	$-31.04M	$-28.33M
High Forecast	$-38.02M	$-40.56M	$-37.98M	$-28.39M	$-30.31M	$-31.04M	$-28.33M
Low Forecast	$-38.02M	$-40.56M	$-37.98M	$-38.27M	$-48.56M	$-31.04M	$-28.33M
Surprise %	-	-	-	-	-	-	-

Disc Medicine's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IRON's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Disc Medicine SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Disc Medicine's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IRON last annual SG&A of $NaN (undefined).

Disc Medicine EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-
Avg Forecast	$-1.27	$-1.35	$-1.27	$-1.14	$-1.21	$-1.04	$-1.10
High Forecast	$-1.27	$-1.35	$-1.27	$-0.95	$-1.01	$-1.04	$-1.10
Low Forecast	$-1.27	$-1.35	$-1.27	$-1.28	$-1.62	$-1.04	$-1.10
Surprise %	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Disc Medicine's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IRON previous annual EPS of $NaN (undefined).

Disc Medicine Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
BMEA	Biomea Fusion	$6.28	$22.75	262.26%	Buy
OLMA	Olema Pharmaceuticals	$8.28	$28.50	244.20%	Buy
FENC	Fennec Pharmaceuticals	$4.64	$15.75	239.44%	Buy
ACRV	Acrivon Therapeutics	$6.50	$21.83	235.85%	Buy
LRMR	Larimar Therapeutics	$6.08	$20.33	234.38%	Buy
ABOS	Acumen Pharmaceuticals	$2.37	$7.00	195.36%	Buy
DAWN	Day One Biopharmaceuticals	$13.62	$38.80	184.88%	Buy
GPCR	Structure Therapeutics	$32.71	$92.40	182.48%	Buy
ANAB	AnaptysBio	$20.31	$52.00	156.03%	Buy
TERN	Terns Pharmaceuticals	$5.60	$14.25	154.46%	Buy
ADAG	Adagene	$2.09	$5.00	139.23%	Buy
MLYS	Mineralys Therapeutics	$12.60	$30.00	138.10%	Buy
MLTX	MoonLake Immunotherapeutics	$49.82	$79.33	59.23%	Buy
CNTA	Centessa Pharmaceuticals	$16.74	$23.25	38.89%	Buy
AMLX	Amylyx Pharmaceuticals	$5.23	$6.67	27.53%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
CRNX	Crinetics Pharmaceuticals	$56.07	$70.14	25.09%	Buy
IRON	Disc Medicine	$62.55	$72.50	15.91%	Buy
TRDA	Entrada Therapeutics	$17.93	$20.00	11.54%	Buy
MORF	Morphic	$56.99	$57.00	0.02%	Hold

IRON Forecast FAQ

Is Disc Medicine a good buy?

Yes, according to 12 Wall Street analysts, Disc Medicine (IRON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 91.67% of IRON's total ratings.

What is IRON's price target?

Disc Medicine (IRON) average price target is $72.5 with a range of $43 to $112, implying a 15.72% from its last price of $62.65. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Disc Medicine stock go up soon?

According to Wall Street analysts' prediction for IRON stock, the company can go up by 15.72% (from the last price of $62.65 to the average price target of $72.5), up by 78.77% based on the highest stock price target, and down by -31.36% based on the lowest stock price target.

Can Disc Medicine stock reach $90?

IRON's highest twelve months analyst stock price target of $112 supports the claim that Disc Medicine can reach $90 in the near future.

What is Disc Medicine's current price target trend?

3 Wall Street analysts forecast a $90.33 price target for Disc Medicine (IRON) this month, up 44.18% from its last price of $62.65. Compared to the last 3 and 12 months, the average price target increased by 32.80% and increased by 4.15%, respectively.

What are Disc Medicine's analysts' financial forecasts?

Disc Medicine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-95.53M (high $-89.675M, low $-108M), average SG&A $0 (high $0, low $0), and average EPS is $-3.349 (high $-3.154, low $-3.763). IRON's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-151M (high $-145M, low $-155M), average SG&A $0 (high $0, low $0), and average EPS is $-5.034 (high $-4.842, low $-5.172).